Safety of immune checkpoint inhibitor rechallenge after severe immune-related adverse events: a retrospective analysis

Immune checkpoint inhibitors (ICIs) present clinicians with the challenge of managing immune-related adverse events (irAEs), which can range from mild to severe due to immune system activation 1. While guidelines recommend discontinuing ICIs for grade 3 partial and all grade 4 irAEs, there is growin...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Céline Eldani, Marie Kostine, Maxime Faure, Estibaliz Lazaro, Claire Rigothier, Jean Baptiste Hiriart, Bérénice Teulières, Florian Poullenot, Magalie Haissaguerre, Maeva Zysman, Rémi Veillon, Charlotte Vergnenegre, Nahema Issa, Charlotte Domblides, Sorilla Mary-Prey, Marie Beylot-Barry, Anne Pham-Ledard, Caroline Dutriaux, Guilhem Sole, Fanny Duval, Emilie Gerard
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2024-07-01
Serie:	Frontiers in Oncology
Soggetti:	immune checkpoint inhibitors (ICIs) immune related adverse events (irAEs) rechallenge neurological immune-related adverse events myocarditis
Accesso online:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1403658/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!